

C4 BINDING TO ARTIFICIAL SYSTEMS

Angeline REBOUL, Marie-Bernadette VILLIERS, Nicole M. THIELENS and Maurice G. COLOMB

Centre d'Etudes Nucléaires de Grenoble, DRF, Laboratoire de Biologie Moléculaire et Cellulaire, 85 X and Université Scientifique et Médicale de Grenoble, ERA CNRS no. 695, Unité INSERM no. 238, 38041 Grenoble cedex, France

Received 22 July 1981

1. Introduction

Activation of complement by the classical pathway contributes to the non-specific defence of vertebrates against infection; it represents the triggering of a cascade system of proteolytic complex enzymes, $C\bar{1}$, the $C3$ and the $C5$ convertases. The $C3$ convertase is a bimolecular complex of proteins $C4b$ and $C2a$ in which $C2a$ contains the catalytic site able to proteolyse $C3$ into two biologically active peptides $C3a$ and $C3b$. $C4b$ is the non-catalytic component of the $C3$ convertase [1,2].

The cleavage of $C4$ by $C\bar{1}$ s leads to a metastable activated fragment, $C4b$, by inducing the transient release of a reactive acyl group, from a thioester linkage in the native molecule; liberation of a free sulfhydryl group accompanies the proteolysis of $C4$ into $C4b$ and $C4a$ [3,4]. Binding of $C4b$ to acceptor surfaces via the activated acyl group is the first step in the formation of $C3$ convertase. Both membranes [5] and Ig [6,7] can act as acceptor of $C4b$; the respective participation of each is as yet not well defined. The efficiency of the binding mechanism is low and

only a few percent of the $C4b$ molecules have been shown to be hemolytically active [8]. This raises the problem of the reactivity of bound $C4b$ towards $C2$ and the regulatory proteins $C4bp$ and I .

A sequential molecular analysis of the different steps involved in the formation of the $C3$ convertase is necessary to understand the whole sequence. We have studied the binding of $C4b$ to two acceptor systems: Sepharose and sheep erythrocyte stroma. The results reported show that the binding of $C4b$ to acceptors is confined only to molecules produced in close proximity to these acceptors. Sepharose, sheep erythrocyte stroma and particulate Ig act as acceptors taking the $EAC\bar{1}$ system as a reference.

2. Materials and methods

All chemicals were of analytical grade.

Human citrated plasma was obtained from the Centre de Transfusion Sanguine (Grenoble) and serum prepared as in [9].

Human complement components were purified as in [10] for $C\bar{1}r$ - $C\bar{1}s$ complex, $C\bar{1}r$, $C\bar{1}s$ and [11] for $C4$.

SDS-PAGE of proteins was as in [9] using 5% (w/v) acrylamide gels. ^{125}I -Labelling of $C4$ and $C\bar{1}s$ -cleaved $C4$ was by the method in [12] or with lactoperoxidase as in [11]. ^{125}I was measured with a MR 480 Kontron counter in the various solutions or in 1 mm gel slices after SDS-PAGE.

Proteins were estimated according to [13] or from their A_{280} for purified proteins using, respectively, $E_{1\text{ cm}}^{1\%} = 10, 11.5, 9.5, 10.6$ and 14 for $C4$ [3], $C\bar{1}r$, $C\bar{1}s$, $C\bar{1}r$ - $C\bar{1}s$ complex, and IgG [10].

Antibodies to ovalbumin were raised in rabbits

Abbreviations: SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; STI, soybean trypsin inhibitor; Ig, immunoglobulins; Ag, antigen; DFP, di-isopropylphosphorofluoridate; NPGb, *p*-nitrophenyl-*p'*-guanidinobenzoate; PBS, 10 mM phosphate buffer (pH 7.2) containing 145 mM NaCl; DGVB²⁺, 5 mM veronal (barbitone), 142 mM NaCl, 2.5% glucose, 0.05% gelatin, 0.5 mM MgCl₂, 0.15 mM CaCl₂ (pH 7.5); EA, erythrocytes sensitized with specific antibodies; $EAC\bar{1}$ or $EAC\bar{1}$, EA bearing proenzymic or activated $C\bar{1}$; $ICC\bar{1}$ or $ICC\bar{1}$, immune complexes bearing proenzymic or activated $C\bar{1}$

Nomenclature: Components of complement follow that recommended by World Health Organization (1968); a bar indicates the activated state of a component

according to [14]. Total immunoglobulins were purified by Na_2SO_4 precipitation [15]. Specific antibodies were purified by immunoabsorption chromatography on a column of ovalbumin–Sephacrose 4B.

EACI^- were prepared from sheep erythrocytes (Bio-Merieux) sensitized with rabbit hemolysin (Behring) at a final dilution of 1:1000; EA were suspended in human serum containing 1 mM NPGB at 10^9 cells/ml and incubated for 30 min at 0°C to allow fixation of CI; after centrifugation and washing at 4°C with DGVB^{2+} supplemented with 1.5 mM CaCl_2 , EACI^- were resuspended in this buffer at 10^9 cells/ml and activated 45 min at 37°C to EACI^- .

Proteins were coupled to Sepharose 4B as in [16]. After activation of Sepharose 4B with CNBr (1 g CNBr for 5 ml packed Sepharose), proteins were coupled overnight at 4°C in 0.1 M NaHCO_3 , 0.1 M NaCl. The CIr-CI^- complex was coupled in 10 mM triethanolamine–HCl, 100 mM NaCl, 5 mM CaCl_2 (pH 8.0) and non-covalently bound proteins washed out by 1 M propionic acid containing 1 M NaCl. Sepharose was resuspended in twice its packed volume of buffer for subsequent use.

CI^- DFP was obtained by blocking the active site of CI^- s by incubation for 1 h at 37°C adding 5 mM DFP at 0 and 30 min. Calcium-dependent binding of CI^- s to Sepharose– CI^- s. Sepharose– CI^- DFP and Sepharose– CIr , in 50 mM Tris–HCl, 150 mM NaCl, 5 mM CaCl_2 (pH 7.4), was done by incubation for 15 min at 4°C with CI^- s in equivalent amount to the Sepharose-bound protein.

To prepare Sepharose– ICCI^- , 1 ml packed Sepharose–ovalbumin, corresponding to 4 mg bound ovalbumin, was suspended for 15 min at 4°C in 10 ml 50 mM Tris–HCl, 150 mM NaCl (pH 7.4) containing 15 mg of anti-ovalbumin Ig. The suspension was washed at 4°C by 30 ml 50 mM Tris–HCl, 150 mM NaCl, 5 mM CaCl_2 (pH 7.4) and 20 ml of the same buffer containing 1 mM NPGB, then incubated for 30 min at 4°C in 20 ml human serum containing 1 mM NPGB. After this incubation the Sepharose was washed at 4°C by 20 ml 50 mM Tris–HCl, 100 mM NaCl, 50 mM CaCl_2 , 1 mM NPGB (pH 7.4) and 30 ml of the same buffer without NPGB. Sepharose– ICCI^- was then resuspended in the last buffer, incubated for 30 min at 37°C , filtered and this step was repeated once leading to the activation of Sepharose– ICCI^- to Sepharose– ICCI^- . The same protocol was used to prepare Sepharose–Ig anti-ovalbumin CI^- from Sepharose–Ig anti-ovalbumin. The activation steps

were in 50 mM Tris–HCl, 150 mM NaCl, 5 mM CaCl_2 (pH 7.4).

Sheep erythrocyte stroma was obtained by hypotonic lysis of sheep erythrocytes [17]. To prepare stroma– CI^- s, a 0.5 mg protein/ml suspension of stroma in PBS was incubated for 17 h at 20°C with 1% (v/v) glutaraldehyde, washed, resuspended at the same dilution in PBS containing CI^- s and incubated for 5 h at 20°C . Unreacted glutaraldehyde was saturated by 112 mM lysine.

To measure C4b binding, particles were incubated with ^{125}I -labelled C4 for 30 min at 37°C . Particles were separated by centrifugation and washed repeatedly until the radioactivity of the supernatants reached background level. Proteolysis of C4 was assessed from SDS–PAGE of the first supernatant.

The different systems used are shown in table 1.

3. Results

3.1. C4b binding to EACI^-

C4b binds to EACI^- (fig.1); SDS–PAGE of the supernatants at the end of the incubation showed that all the C4 is proteolysed. In contrast, with EA, only a low level of fixation of C4 and fluid phase CI^- s-cleaved C4 was measured. The binding of C4b does not show a linear variation with increasing amounts of EACI^- : this may reflect a disparity between the




Fig.1. C4b binding to EACI^- : $5 \mu\text{g}$ ^{125}I -labelled C4 were incubated as in section 2 in DGVB^{2+} supplemented with 1.5 mM CaCl_2 with varying concentrations of EACI^- (●), EA (○) or EA + $2.5 \mu\text{g}$ CI^- s (■). Washes were with the incubation buffer as in section 2.

kinetics of C4 proteolysis and C4b deposition.

Calculation from the amount of C4b bound by 4×10^8 EAC \bar{I} gives ~ 4500 molecules C4b bound/erythrocyte.

3.2. C4b binding to Sepharose—subcomponents of C \bar{I}

Fig.2 shows that Sepharose behaves as an acceptor for C4b; the fixation of C4b increases linearly with increasing concentrations of Sepharose. The link between C4b and Sepharose is resistant to 1% SDS but is sensitive to 50 mM methylamine at pH 10.4 consistent with a nucleophile-sensitive covalent bond. The low binding of C4 to Sepharose—C \bar{I} sDfP (table 1, system 2) which does not cleave C4 as compared to Sepharose—C \bar{I} s (table 1, system 1) indicates that proteolysis of C4 is a necessary step for its binding.

Assuming that C \bar{I} s accounts for half of the total protein bound on Sepharose—(C \bar{I} r—C \bar{I} s), 0.2 mg C \bar{I} s is bound/ml Sepharose—(C \bar{I} r—C \bar{I} s) and 0.86 mg/ml of Sepharose—C \bar{I} s: therefore the results in fig.2 show that Sepharose—(C \bar{I} r—C \bar{I} s) (table 1, system 3) binds ~ 7 -times more C4b/C \bar{I} s than Sepharose—C \bar{I} s (table 1, system 1).

As C \bar{I} s is able to dimerize in the presence of calcium, Sepharose—dimeric C \bar{I} s was prepared either from Sepharose—monomeric C \bar{I} s or Sepharose—




Fig.2. C4b binding to Sepharose—subcomponents of C \bar{I} : 5 μ g 125 I-labelled C4 were incubated as in section 2 in 50 mM Tris-HCl, 100 mM NaCl, 5 mM CaCl $_2$ (pH 7.4) with varying concentrations of Sepharose—C \bar{I} s (●) or Sepharose—(C \bar{I} , S) (○); the values measured with Sepharose—C \bar{I} sDfP, Sepharose—C \bar{I} sDfP Ca $^{2+}$ —C \bar{I} s, Sepharose—C \bar{I} s—Ca $^{2+}$ —C \bar{I} s and Sepharose—C \bar{I} r—Ca $^{2+}$ —C \bar{I} s are comprised in the hatched zone. Washes were with the incubation buffer as in section 2 then with 1% (w/v) aqueous SDS.

Table 1
Putative representation of the systems used as C4b acceptors

1. Sepharose—C \bar{I} s	C \bar{I} s covalently bound in the absence of calcium
2. Sepharose—C \bar{I} sDfP	C \bar{I} sDfP covalently bound as in 1
3. Sepharose $\begin{cases} \text{C}\bar{\text{I}}\text{r} \\ \text{Ca}^{2+} \\ \text{C}\bar{\text{I}}\text{s} \end{cases}$	C $\bar{\text{I}}\text{r}$ —C $\bar{\text{I}}\text{s}$ complex covalently bound in the presence of calcium
4. Sepharose—C \bar{I} s—Ca $^{2+}$ —C \bar{I} s	C \bar{I} s first bound as in 1; second non-covalent binding of C \bar{I} s in the presence of calcium
5. Sepharose—C \bar{I} sDfP—Ca $^{2+}$ —C \bar{I} s	As for 4 but with C \bar{I} sDfP in the first binding
6. Sepharose—C $\bar{\text{I}}\text{r}$ —Ca $^{2+}$ —C \bar{I} s	C $\bar{\text{I}}\text{r}$ covalently bound first: C \bar{I} s bound in the second step, as in 4 and 5
7. Sepharose—Ig—C1q—C $\bar{\text{I}}\text{r}$ —C \bar{I} s	Ig covalently bound first: C1 fixed from serum in the second step, then activated to C1
8. Sepharose—Ag—Ig—C1q—C $\bar{\text{I}}\text{r}$ —C \bar{I} s	Ag covalently bound first: Ig bound by immune affinity in the second step; then C1 fixed and activated in the third step, as in 7
9. Stroma—C \bar{I} s	C \bar{I} s covalently bound, in the absence of calcium




Fig.3. C4b binding to Sepharose-Ig anti-ovalbumin C1: 5 μ g 125 I-labelled C4 were incubated as in section 2 in 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl_2 (pH 7.4) containing STI (final conc. 50 μ g/ml) with varying concentrations of Sepharose-Ig anti-ovalbumin C1. Washes were as in section 2 with the incubation buffer without STI then with 1% (w/v) aqueous SDS (●) 2 mg Ig/ml packed Sepharose; (○) 0.2 mg Ig/ml packed Sepharose.

monomeric C1s blocked by DFP, incubated with soluble C1s in 5 mM CaCl_2 . These systems (table 1, systems 4,5) are very inefficient for C4b binding as well as a different Sepharose-C1r-C1s system (table 1, system 6) prepared from Sepharose-C1r incubated with soluble C1s in 5 mM CaCl_2 .

3.3. C4b binding to Sepharose-Ig anti-ovalbumin C1

C4b binds to Sepharose-Ig anti-ovalbumin C1 (table 1, system 7) (fig.3). Anti-ovalbumin Ig was coupled to Sepharose 4B to generate a system comparable to that described to evaluate C4b binding to Sepharose-ICC1 (table 1, system 8). From an amount of 0.075 ml packed Sepharose, the amount of bound C4b increases proportionally to the Ig: Sepharose ratio. For lower amounts of Sepharose the hardly-detectable bound C4b, in the case of the lowest Ig concentration, may be attributed to particulate C1 being limiting.

3.4. C4b binding to Sepharose-ICC1

Analysis of C4b binding to Sepharose-ICC1 (table 1, system 8) (fig.4) suggests a double localisation: one part of the radioactivity which is eluted by 1 M propionic acid corresponds to C4b binding to the Ig, the other part which is not eluted even by additional washes by 1% aqueous SDS corresponds to covalent binding to Sepharose. Only the binding to Sepharose




Fig.4. C4b binding to Sepharose-ICC1: 5 μ g (●) or 2.5 μ g (○) of 125 I-labelled C4 were incubated as in section 2 in 50 mM Tris-HCl, 100 mM NaCl, 5 mM CaCl_2 (pH 7.4) containing STI (final conc. 50 μ g/ml) with varying concentrations of Sepharose-ICC1. Sequential washes were as in section 2 with the incubation buffer without STI, 50 mM Tris-HCl, 1 M NaCl (pH 7.4), 1 M propionic acid and 1% (w/v) aqueous SDS. Broken lines indicate the percentage of the input eluted by 1 M propionic acid.

increases as a function of Sepharose-ICC1 concentration and appears proportional to the amount of C4 for the two quantities of C4 assayed.

SDS-PAGE of a propionic-acid eluate is shown in fig.5: the distribution of the radioactivity is con-




Fig.5. SDS-PAGE radioactivity pattern of a propionic acid eluate from Sepharose-ICC1 after C4b binding. The propionic acid eluate corresponding to the highest radioactivity eluted in fig.4 was dialyzed against water and lyophilized. The lyophilysate was reduced and alkylated. Electrophoresis and counting were as in section 2. The arrows point to the position of the chains of C4.




Fig.6. C4b binding to erythrocyte stroma-C1s: 5 μ g 125 I-labelled C4 were incubated as in section 2 in 50 mM Tris-HCl, 100 mM NaCl, 5 mM CaCl₂ (pH 7.4) containing STI (final conc. 50 μ g/ml) with varying concentrations of erythrocyte stroma-C1s. Washes were as in section 2 with the incubation buffer without STI. For each point the binding of fluid phase C1s-cleaved C4 was subtracted. The erythrocyte stroma-C1s were prepared using 0.16 (○) or 0.32 (●) mg C1s/mg stroma protein.

sistent with the pattern of radioactivity of 125 I-labelled C4b for β and γ chains but shows a very sharp decrease of radioactivity in α' chain concomitant with the presence of two additional higher-molecular-mass radioactive peaks.

3.5. C4b binding to erythrocyte stroma-C1s

C4b binds to stroma-C1s (table 1, system 9) as a function of the amount of stroma (fig.6). The C1s to stroma ratio appears to influence C4b binding; doubling C1s for the same amount of stroma induces a doubling of bound C4b.

Assuming that the yield of stroma from the starting erythrocytes is 100%, one can calculate that 450 molecules of C4b are bound per erythrocyte, based on the highest value of C4b binding.

4. Discussion

As binding of a metastable activated form of C4 represents a critical step in the formation of the C3 convertase, the binding of this component was examined using Sepharose and erythrocyte stroma as acceptors, in reference to the EAC1 system.

C4 binds to Sepharose after cleavage by C1s bound to the same matrix. When C4 is proteolysed by soluble

C1s no significant binding occurs, which is also observed with EA as acceptor. Several models in which C1s is located at different distances from the matrix (table 1) clearly show that the distance between the protease active site and the acceptor is the limiting factor in C4b binding, as shown for C3b binding to Sepharose-trypsin [18]. C1s directly bound to Sepharose (table 1, system 1) leads to a net binding of C4b whereas when it is at some distance no binding occurs. With a spacer as small as C1s itself or C1sDFP (table 1, systems 4,5) only negligible amounts of C4b bind in spite of a total cleavage of C4; in this case the amount of C4b bound is of the same order as when C4 is incubated with Sepharose-C1sDFP (table 1, system 2) which does not cleave C4. In the case of systems 7 and 8 (table 1) where, respectively, Ig-C1q-C1r and Ag-Ig-C1q-C1r are between C1s and the acceptor Sepharose, the binding of C4 on the matrix can be explained by a suitable orientation of C1s.

The immediate proteic environment of C1s seems to influence the efficiency of C4b binding: when the C1r-C1s complex is covalently linked to Sepharose (table 1, system 3), the system appears more efficient than when C1s is bound alone (table 1, system 1). In the same light the efficient binding of C4b reported above for systems 7 and 8 (table 1) can also be attributed to the integration of C1s in C1, in close proximity to C1r. The role of C1r could be either to modulate the active site of neighbouring C1s or to orient C4. The low binding of C4b observed with system 6 (table 1) in which C1r and C1s are sequentially bound can be explained by the only very partial reconstitution of the C1r-C1s complex.

Both Sepharose and Ig participate as acceptor of C4b on Sepharose-ICC1 (table 1, system 8). However more C4b binds to Sepharose than to Ig; the decrease of Ig-bound C4b with increasing concentrations of Sepharose-ICC1 suggests that C4b has a higher affinity for Sepharose than for Ig. The electrophoretic pattern of C4b eluted from Ig by propionic acid indicates two high-molecular mass peaks which could be accounted for by α' - α' and α' -heavy Ig chain associations as observed with C4b bound to immune complex aggregates [7].

Fixation of C4b on stroma-C1s (table 1, system 9) is of the same order of magnitude as on EAC1. EAC1 and to a less degree stroma-C1s show pseudo-saturation curves for the fixation of C4b with increasing concentrations of acceptor, suggesting a difference between the kinetics of proteolysis and binding of C4b.

Acknowledgements

This work was supported partly by the Délégation Générale à la Recherche Scientifique et Technique (contrat 80.7.0297) and the Fondation pour la Recherche Médicale.

References

- [1] Müller-Eberhard, H. J. (1979) in: *Modulation of Protein Function* (Atkinson, D. E. and Fox, C. F. eds) vol. 13, pp. 219–232, Academic Press, New York.
- [2] Porter, R. R. (1980) *Proc. R. Soc. Lond. B* 210, 477–498.
- [3] Reboul, A., Thielens, N., Villiers, M. B. and Colomb, M. G. (1980) *FEBS Lett.* 115, 118–122.
- [4] Janatova, J. and Tack, B. F. (1981) *Biochemistry* 20, 2394–2402.
- [5] Law, S. K., Lichtenberg, N. A., Holcombe, F. H. and Levine, R. P. (1980) *J. Immunol.* 125, 634–639.
- [6] Goers, J. W. F. and Porter, R. R. (1978) *Biochem. J.* 175, 675–684.
- [7] Campbell, R. D., Dodds, A. W. and Porter, R. R. (1980) *Biochem. J.* 189, 67–80.
- [8] Cooper, N. R. and Müller-Eberhard, H. J. (1968) *Immunochemistry* 5, 155–169.
- [9] Arlaud, G. J., Reboul, A., Meyer, C. M. and Colomb, M. G. (1977) *Biochim. Biophys. Acta* 458, 215–226.
- [10] Arlaud, G. J., Sim, R. B., Duplaa, A. M. and Colomb, M. G. (1979) *Mol. Immunol.* 16, 445–450.
- [11] Reboul, A., Thielens, N., Villiers, M. B. and Colomb, M. G. (1979) *FEBS Lett.* 103, 156–161.
- [12] Bolton, A. E. and Hunter, W. M. (1973) *Biochem. J.* 133, 529–539.
- [13] Bradford, M. M. (1976) *Anal. Biochem.* 72, 248–254.
- [14] Porter, R. R. (1955) *Biochem. J.* 59, 405–410.
- [15] Prahl, J. W. and Porter, R. R. (1968) *Biochem. J.* 107, 753–763.
- [16] March, S. C., Parikh, I. and Cuatrecasas, P. (1974) *Anal. Biochem.* 60, 149–152.
- [17] Steck, T. L. and Kant, J. A. (1974) *Methods Enzymol.* 31A, 172–180.
- [18] Sim, R. B., Twose, T. M., Patterson, D. S. and Sim, E. (1981) *Biochem. J.* 193, 115–127.